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Background: Monocolina K is a fermented product of rice and red yeast (RYR) (Monascus 
purpureus) and has been used by the Chinese for many centuries as a food preservative and for its 
medicinal properties. It is a potent inhibitor of HMG-CoA reductase and is known as substance, which 
lower serum cholesterol levels.
Aim: To investigate the hipolipimiant effect of Monocolina K in patient with hipercolesterolemia 
with moderate cardiovascular SCORE risk.
Methods: A total of 30 patients (mean age: 47,8 ± 1,8 years, 52 % males) who had a total 
cholesterol level of > 5,2 mmol/L were included in the study and allocated to receive a “No – Colest” 
which contain 10 mg of Monocolina K for 6 weeks. The 10-years risk of cardiovascular events was 
calculated according to cardiovascular risk SCORE before and after the treatment. As a primary outcome 
measure, we compared the before-after difference in lipid levels for patients included in the study.
Results: LDL (low density lipoprotein) cholesterol was lowered from 4,19± 0,22 to 3,51± 0,14
mmol/L.
(-16,2%) (p<0,001), total cholesterol from 6,46± 0,27 to 5,28± 0,16 mmol/L (-18,3%) (p<0,001), 
the TG (triglycerides) was reduced from 1,89± 0,27 to 1,61± 0,14 mmol/L (-14,8%) (p<0,05), and HDL 
(high density lipoprotein) have also been lowered from 1,35± 0,05 to 1,26± 0,02 mmol/L
(-6,7%) (p>0,05) in the intervention group. Any side effects haven’t been noticed.
The lipid lowering effect resulted in reducing of cardiovascular risk as measured with SCORE 
chart, that changed from 3,85% to 2,5%.
Conclusions: The RYR formulation under study was well tolerated and effective in lowering 
LDL, total cholesterol and TG as well as the cardiovascular risk in this study population.
Trial registration: Clinicaltrials.gov, nr: NCT01558050 
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